nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Bipolar Disorders"

 

Lithium Use During Pregnancy and Maternal and Infant Outcomes
July 13, 2018   

Lithium is a staple and highly effective medication for the treatment of bipolar disorder; however, past data have indicated somewhat mixed data regarding the teratogenic effects of lithium use during pregnancy...
 Continue reading
2018 APA Highlight: Immunotherapies in Schizophrenia and Bipolar Disorder
May 5, 2018   

During the 2018 American Psychiatric Association (APA) Annual Meeting, Dr. Mark Weiser discussed the latest therapies being investigated to treat inflammation in schizophrenia and bipolar disorder...
 Continue reading
FDA Warns of Serious Immune System Reaction with Lamotrigine
April 25, 2018   

FDA issues warning that lamotrigine can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system...
 Continue reading
Updated Recommendations For Treatment of Tardive Syndrome
April 20, 2018   

The American Academy of Neurology (AAN) has released updated recommendations for treatment of tardive syndromes...
 Continue reading (Members only)
FDA Approves Lurasidone for Pediatric Bipolar Depression
March 8, 2018   

The US Food and Drug Administration (FDA) has approved lurasidone for the treatment of bipolar depression in pediatric patients (ages 10 to 17)...
 Continue reading
Review: Benefits vs. Risks of Aripiprazole During Pregnancy
February 7, 2018   

A systematic literature search and review evaluated the available data on the use of aripiprazole during pregnancy, peripartum and lactation...
 Continue reading
Cognitive Remediation Can Improve Cognitive Function in Bipolar Disorder
November 3, 2017   

Cognitive remediation produced significant improvements over an active control in several cognitive domains...
 Continue reading
Aripiprazole Maintena Approved for Bipolar Maintenance Treatment
August 1, 2017   

On July 28, 2017, the U.S. Food and Drug Administration approved the atypical antipsychotic Abilify Maintena (aripiprazole) as a maintenance monotherapy treatment for patients with Bipolar I disorder...
 Continue reading
FDA Update: New Warning Added to Antipsychotic Labels
April 6, 2017   

The U.S. Food and Drug Administration (FDA) has approved a labeling update for all antipsychotic medications adding a new warning to the prescribing information....
 Continue reading
Guidelines for the Recognition and Treatment of Depression with Mixed Features
March 10, 2017   

The Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) incorporated a "mixed features" specifier that recognizes the idea of mood disorders as lying on a spectrum and acknowledges the coexistence of subthreshold symptoms of (hypo)mania during a major depressive episode (or of subthreshold symptoms of depression co-occurring with a manic episode)...
 Continue reading
123
Top of Page